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Abstract Short cytoplasmic domains of integrin heterodlmers 
are crucial for transduction of signals generated by adhesion of 
cells to the extracellular matrix. Here, we describe the use of 
peptides mimicking the intracellular tails of integrin cr& to 
assay in vitro associations with cytoskeletal proteins. Our results 
suggest that the focal adhesion protein, paxillln, may interact 
directly with the intracellular region of the mtegrm l.31 subunit. 
Paxillin is known to form stable complexes with several signaling 
molecules, including focal adhesion kinase. Physical interaction 
between paxillin and the fit cytoplasmic domain suggests a model 
in which paxillin may function as a key intermediary in integrin- 
mediated signal transduction. 
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1. Introduction 
Cells adhere to the extracellular matrix (ECM) through 
heterodimeric (c$) transmembrane receptors of the integrin 
family [1,2]. Integrin extracellular domains contact the ECM 
at specialized structures known as focal adhesion plaques 
[3,4], in which the intracellular domains of integrins provide 
nucleation sites for the assembly of protein complexes that 
bind actin filaments [5,6]. In addition to providing structural 
connections between the ECM and the actin cytoskeleton, 
integrin receptor stimulation generates intracellular signals 
[7-91 which may contribute to the regulation of anchorage- 
dependent cell growth, including tyrosine phosphorylation of 
a number of cellular proteins [lo, 111. Since integrin cytoplas- 
mic regions are short and lack intrinsic enzymatic activity, 
integrin-mediated signal transduction must rely on the recruit- 
ment and activation of signaling molecules appropriately po- 
sitioned in proximity to integrin intracellular domains. Nota- 
bly, plating of cells on fibronectin [12,13] or clustering of p1 
integrins by antibody cross-linking [14] results in tyrosine 
phosphorylation of a non-receptor protein tyrosine kinase 
(PTK), FAK, that localizes to focal adhesions [15-211. FAK 
is capable of forming signaling complexes with several pro- 
teins including paxillin [22-241, a focal adhesion protein found 
in association with vinculin [25] that is multiply phosphory- 
lated following integrin receptor engagement [26-3 11. 
Though integrin cytoplasmic domains are apparently criti- 
cal for the transduction of regulatory signals accompanying 
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cell adhesion [32,33], the immediate consequences of integrin 
occupancy and the mechanism of FAK activation remain 
poorly understood. Much effort has focused on the identifica- 
tion of proteins that may interact with integrin cytoplasmic 
tails. In vitro binding assays using synthetic peptides based on 
the cytoplasmic regions of integrin subunits have elucidated 
structural features of focal adhesion complexes. Integrin pr 
peptides have been shown to bind to the actin-associated pro- 
tein, a-actinin [34,35] and to talin [36,37]. Talin provides an 
indirect linkage to actin filaments through complexes with 
vinculin [38], which in turn, associates with a-actinin [39,40] 
and another actin-binding protein, tensin [41]. A recent study 
reported direct binding of FAK to pr cytoplasmic peptides, 
utilizing p1 sequences distinct from those important for talin 
or a-actinin recognition [42]. Evidence was also presented for 
association of paxillin with pi in extracts of chicken embryo 
(CE) fibroblasts; however, binding of both FAK and paxillin 
was apparently mediated by the same membrane proximal 
region of the pi subunit [42], and the known physical inter- 
action between FAK and paxillin [22-241 precluded resolution 
of whether paxillin associated directly or indirectly with inte- 
grin. 
Here, we use peptides that mimic intracellular domains of 
the human fibronectin receptor (asPr> in binding assays to 
explore the role of paxillin in integrin-mediated signaling. 
We present new evidence that paxillin may interact directly 
with the cytoplasmic tail of the pi subunit. These results sug- 
gest a model in which paxillin may act as an important inter- 
mediary in transduction of signals generated by cell adhesion 
through integrins. 
2. Materials and methods 
2.1. Materials 
Immunoblotting was performed using the following monoclonal 
antibodies: anti-paxillin (Zymed Laboratories, South San Francisco, 
CA); anti-FAK and anti-ezrin (Transduction Laboratories, Lexing- 
ton, KY); anti-talin, anti-a-actinin, anti-vinculin (Sigma Immuno- 
chemicals, St. Louis, MO); anti-tensin (Chemicon International, Te- 
mecula, CA); anti-FLAG M2 monoclonal antibody (Eastman Kodak 
Co., New Haven, CT) and polyclonal anti-human Bi integrin cyto- 
plasmic domain (Chemicon International). Protein tyrosine phosphor- 
ylation was examined with anti-phosphotyrosine antibody RC20 
(Transduction Laboratories). 
2.2. Peptide synthesis 
Peptides corresponding to human integrin as and Bi cytoplasmic 
tails were synthesized by standard protocols using Fmoc chemistry on 
an Applied Biosystems peptide synthesizer, Model 430A (Foster City, 
CA)..Amino acid sequences of peptides were confirmed using an Ap- 
plied Biosystems Model 477A sequencer. The procedure for cross- 
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linking of ~1s and PI peptides to a biotinylated linker will be reported 
elsewhere (Tanaka et al., in preparation). The M, of the a& peptide 
construct was verified by mass spectrometry; m/z=9748.46, calculated 
for C446H6900121N112S6=9749.46. 
2.3. Cell culture and preparation of extracts 
KB cells were obtained from the Japanese Cancer Research Re- 
sources Bank and were cultured in DMEM supplemented with 10% 
fetal bovine serum, 50 U of penicillin per ml, and 50 kg of strepto- 
mycin per ml. Adhesion of KB cells to ECM proteins was examined 
using Cytomatrix Cell Adhesion Strips (Chemicon International) ac- 
cording to the supplier’s specifications. Adherent cells stained with 
0.2% crystal violet were quantitated by measuring absorbance at 
540 nm. To prepare cell extracts, KB monolayers (approx. 1 x lo7 
cells) plated on lOO-mm dishes coated with fibronectin at 10 pg/ml 
were washed twice with phosphate-buffered saline (PBS) containing 
500 FM NasV04. For peptide binding assays, cells were lysed for 15 
min at 4°C in 1% Nonidet P-40 buffer (10 mM Tris-Cl, pH 7.5; 150 
mM NaCl; 1% Nonidet P-40, 1 mM NasV04, 1 mM phenylmethyl- 
sulfonyl fluoride, and 1 pg/ml each of aprotinin, pepstatin, and leu- 
peptin). Insoluble material was removed by centrifugation at 14000 
rpm for 10 min. Suspended cells were detached from tissue culture 
dishes by treatment with 2 mM EDTA in PBS at 37°C for 15 min, 
harvested by centrifugation, and then lysed in 1% Nonidet P-40 buf- 
fer. For immunoprecipitations with monoclonal antibodies, adherent 
or detached cells were lysed in modified RIPA buffer essentially as 
described [43]. Pre-cleared lysates were incubated with monoclonal 
antibodies for 2 h at 4°C and immune complexes precipitated using 
protein G-Sepharose beads (Pharmacia, Piscataway, NJ). 
2.4. Peptide binding assays 
0.5 ml of total KB cell lysates (500 pg) in 1% Nonidet P-40 buffer 
were rotated for 3 h at 4°C with 20-500 ng of biotin-labeled a& or 
PI peptide conjugated to Dynabeads M-280 Streptavidin (Dynal AS, 
Oslo, Norway). Non-specific binding interactions were blocked by 
pre-incubation of the peptide-conjugated beads in PBS containing 
0.1% bovine serum albumin (BSA) for 1 h at room temperature. 
Cellular proteins complexed with paramagnetic beads were collected 
using a Dynal MPC-E magnetic particle concentrator (Dynal AS). 
Beads were washed five times with 1% Nonidet P-40 buffer prior to 
elution with SDS sample buffer. Some incubations were carried out in 
the presence of 2 pl of polyclonal antiserum generated against the 
human PI integrin peptide. Incubations of cell lysates with paramag- 
netic beads lacking the c~s/3l cross-linked peptide were included as 
negative controls in all experiments. Proteins bound to asp1 beads 
were identified by immunoblotting with antibodies recognizing focal 
adhesion proteins. Bead complexes were analyzed by SDS-PAGE and 
immunoblotting as described 1431. Visualization of proteins on immu- 
noblots was carried out using enhanced chemiluminescence (ECL) 
(Amersham Corp., Arlington Heights, IL). Binding of purified recom- 
binant GST-paxillin to approx. 10 ng of p1 or control paramagnetic 
beads was assayed in 0.5 ml of PBS containing 1% Nonidet-P40 using 
approx. 5 ng of glutathione&transferase (GST)-paxillin fusion pro- 
tein or purified GST control. After extensive washing of beads in PBS 
1% Nonidet-P40, proteins were eluted with SDS sample buffer. GST- 
paxillin binding was assessed by silver staining of SDS gels and by 
immunoblotting with anti-paxillin antibody. 
2.5. Protein expression in E. coli 
Human paxillin was produced in E. coli as a GST fusion using 
vector pGEX-2T (Pharmacia), containing the entire coding region 
of human paxillin cDNA (Y. Masaki, S. Hashimoto and H.S., manu- 
script in preparation) isolated from U937 cells based on the published 
sequence [30]. The 94 kDa GST-paxillin fusion protein was purified 
using glutathione-Sepharose beads as described (Pharmacia). Human 
FAK cDNA [44] was provided by Dr. S.B. Kanner (Bristol-Myers 
Squibb Pharmaceutical Research Institute, Seattle, WA). A C-ter- 
minal fragment of FAK (Q852-H1052) comprising the focal adhesion 
targeting (FAT) domain [22-241 was expressed in E. coli as a FLAG 
epitope-tagged fusion and purified using anti-FLAG M2 affinity ma- 
trix (Eastman Kodak Co.). Paxillin was co-immunoprecipitated from 
KB cell extracts (200 kg) prepared in 1% Triton X-100, 150 mM 
NaCl, 10 mM Tris-Cl pH 7.4, 1 mM EDTA, 0.2 mM NasV04, 0.2 
mM PMSF, 0.5% Nonidet P-40 buffer using 2 pg of purified epitope- 
tagged FAT protein and anti-FLAG M2 antibody. 
3. Results 
3.1. Adhesive properties of human KB cells and adhesion- 
dependent tyrosine phosphorylation of paxillin 
Interaction of paxillin or other focal adhesion proteins with 
fibronectin receptor (a&) cytoplasmic domains was investi- 
gated in human KB carcinoma cells. As depicted in Fig. lA, 
KB cells adhere efficiently to tissue culture wells coated with 
the ECM proteins fibronectin, laminin, collagen type IV, and 
tenascin, consistent with reported expression of ~12, ~13, a5, ~16, 
and /31 integrin subunits at the cell surface [lo]. When we 
compared protein tyrosine phosphorylation patterns in ex- 
tracts of KB cells spread on fibronectin-coated dishes with 
rounded KB cells that were detached from tissue culture 
dishes and kept in suspension, several phosphotyrosine-con- 
taining proteins were significantly enriched in adherent cells 
(Fig. lB,a, compare lanes 1,2). Immunoprecipitation experi- 
ments identified 125 and 68 kDa phosphoproteins as FAK 
([10,14], data not shown) and paxillin (Fig. lB,c), respectively. 
Extracts of cells plated on fibronectin showed enhanced tyr- 
osine phosphorylation of paxillin in immunoprecipitates rela- 
tive to cells kept in suspension (Fig. lB,b, lanes 1,2), establish- 
ing adhesion-dependent regulation of paxillin tyrosine 
phosphorylation in KB cells. These data are in good agree- 
ment with findings in other cell types implicating paxillin as a 
downstream component in integrin-mediated signaling path- 
ways [26-3 11. 
3.2. Design of a heterodimeric peptide mimicking asp1 
cytoplasmic domains 
To assay protein association with intracellular domains of 
the asP1 fibronectin receptor in KB cells, we synthesized a 
heterodimeric peptide composed of sequences identical to 
the cytoplasmic regions of the human ~1s and PI subunits 
(Fig. 2). a5 and p1 peptides were joined to a short, biotin- 
conjugated peptide linker at their amino-termini using a pep- 
tide architecture technique outlined in Section 2. Incorpora- 
tion of biotin into the linker facilitated use of the integrin 
receptor mimic, in conjunction with streptavidin-conjugated 
paramagnetic beads, to affinity-purify cellular proteins bound 
to clspl cytoplasmic tails. Homodimeric (asc~, or plpl) cyto- 
plasmic domain peptides were also generated and linked to 
paramagnetic beads by similar procedures for use in binding 
studies (not shown). 
3.3. Paxillin binding to asp1 beads in extracts of adherent 
KB cells 
Fig. 3a shows immunoblot analyses of a& peptide-asso- 
ciated proteins purified from extracts of KB cells adhering to 
fibronectin. As expected, proteins bound to cx5p1 cytoplasmic 
domain peptides included two proteins, talin and a-actinin, 
known from previous in vitro studies to interact with the p1 
intracellular region [34-371. Isolation of talin and a-actinin 
confirmed the utility of the heterodimeric peptide in identifi- 
cation of proteins that interact with the c15pl cytoplasmic 
domain. c+Actinin bound particularly well to the asp1 peptide 
(Fig. 3a). Incubation with peptide-coated beads produced a 
significant enrichment of a-actinin over marginal protein lev- 
els detected in total cell lysates (TCL), relative to other focal 
adhesion proteins, and a-actinin binding persisted using a 
quantity of beads 25-fold lower (Fig. 3a, lane 4) than that 
at which binding of talin was detected (Fig. 3a, lane 2). Other 
T. Tanaka et al.IFEBS Letters 399 (1996) 53-58 55 
a b 
BSA CO(r) CO(W) TN FN VN LA 
adhesive protein 
Fig. 1. Enhanced tyrosine phosphorylation of paxillin in adherent KB cells. (A) Adhesion of KB cells to various ECM substrates was examined 
as described in Section 2. Each data point represents the mean of 10 replicate microtiter wells coated with adhesive protein. BSA, bovine serum 
albumin; CO(I), collagen type I; CO(IV), collagen type IV; TN, tenascin; FN, fibronectin; VN, vitronectin; LA, laminin. (B) Phosphotyro- 
sine-containing cellular proteins in total cell lysates of suspended (a, lane 1) or fibronectin-plated (a, lane 2) KB cells were examined by immu- 
noblotting with anti-phosphotyrosine antibody. Molecular masses of marker proteins are indicated in kD. Asterisks denote cellular proteins 
which show enhanced phosphorylation on tyrosine in adherent relative to suspended cells. (b) Immunoprecipitation of paxillin from lysates of 
suspended (lane 1) or fibronectin-plated (lane 2) KB cells was performed using anti-paxillin followed by immunoblot analysis with anti-phos- 
photyrosine. (c) Immunoblotting with anti-paxillin confirmed equivalent levels of paxillin in immunoprecipitates from suspended (lane 1) or ad- 
herent (lane 2) KB cells. Arrows indicate paxillin. 
focal adhesion proteins associated with cl& beads in in vitro 
assays were vinculin, and paxillin (Fig. 3a). Neither of these 
proteins has been implicated previously in direct interactions 
with integrin subunits. Rather, in vitro data suggest that vin- 
culin associates with integrin indirectly, through complexes 
with talin [38] or a-actinin [39]; while paxillin is known to 
bind vinculin [25]. Under conditions in which binding of KB 
cellular a-actinin, talin, vinculin, and paxillin to asp1 beads 
was readily detected, no significant associations with endogen- 
ous FAK, tensin (Fig. 3a), p-actin or ezrin (data not shown) 
were observed. 
3.4. Paxillin binding to a& beads in extracts of suspended 
KB cells 
To examine further the binding of paxillin and other focal 
adhesion proteins to a& cytoplasmic domains, we repeated 
peptide binding assays using extracts of suspended KB cells 
(Fig. 3M). By disruption of focal contacts, we hoped to gain 
insight into potentially direct physical interactions of focal 
adhesion proteins with asp1 peptides as opposed to indirect 
interactions dependent upon the presence of existing protein 
complexes in lysates of cells spread on fibronectin. Signifi- 
Fig. 2. Heterodimeric peptide mimicking human fibronectin receptor 
as and p1 cytoplasmic domains. Peptides corresponding to integrin 
as and /31 intracellular regions were synthesized separately and their 
amino-terminal regions were coupled to a peptide linker as summar- 
ized in Section 2. The amino-terminal lysines of as and PI cytoplas- 
mic peptides are presumed to represent the residues just proximal to 
the interface between membrane and cytoplasm [6]. Cysteine was in- 
cluded at the extreme amino-terminus of p1 for peptide coupling. 
The biotin moiety conjugated to the linker permits isolation of pep- 
tide-protein complexes. Biotin is at a position distinct from the cts 
and p1 sequences in our synthetic scheme to reduce steric hindrance 
in binding of intracellular ligands. 
cantly, binding of cellular paxillin (Fig. 3b, lane 2), talin 
and a-actinin (Fig. 3c, lane 2), but not vinculin (Fig. 3b, 
lane 2), to a& beads was detected in extracts of suspended 
KB cells. In addition, interaction of paxillin with asp1 cyto- 
plasmic domain peptides was inhibited in the presence of anti- 
serum generated against a peptide derived from the human p1 
intracellular subunit (Fig. 3b, lane 3). Further studies using 
extracts of suspended cells and beads coated with either 
homodimeric a5 or PI peptides (Fig. 3d) provided evidence 
for selective interaction of paxillin with the PI (Fig. 3d, lane 
4), but not the CQ, (Fig. 3d, lane 3) cytoplasmic tail. 
3.5. Binding of GST-paxillin to the PI cytosplamic domain 
In vitro studies with purified recombinant paxillin were 
performed to establish whether paxillin binding to p1 may 
occur directly (Fig. 4). Full-length human paxillin was ex- 
pressed in E. coli as a GST fusion protein, and purified 
GST-paxillin was incubated with PI-coated or uncoated con- 
trol beads as described in Section 2. Bead complexes were 
resolved by SDS-PAGE and analyzed by immunoblotting 
with anti-paxillin (Fig. 4a) or by silver staining (Fig. 4b). 
Immunoblotting experiments detected apparent physical asso- 
ciation of GST-paxillin with p1 beads (Fig. 4a, lane 3). Sig- 
nificant levels of non-specific binding of GST-paxillin to un- 
coated beads were not observed (Fig. 4a, lane 2). Silver 
staining of duplicate SDS gels was consistent with direct 
and specific interaction of GST-paxillin with the p1 cytoplas- 
mic peptide (Fig. 4b, compare lanes 2,3). Importantly, no 
binding of purified GST to o1 was detected (Fig. 4b, lane 
l), indicating that interaction of GST-paxillin with the p1 
cytoplasmic tail is unlikely to depend on the GST moiety. 
3.6. KB cellular paxillin associates with the C-terminal domain 
of FAK 
Studies in other cell types have established formation of a 
signaling complex composed of FAK and paxillin [22-241, 
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Fig. 3. Paxillin from lysates of adherent or suspended KB cells binds to CLSP~ beads. Total cell lysates (TCL, lane 1) from fibronectin-plated or 
suspended KB cells were incubated with CLSP~ beads as described in Section 2. Proteins bound to beads were identified by immunoblotting with 
monoclonal antibodies recognizing the indicated focal adhesion proteins. Extracts of adherent KB cells (a) were incubated with 500 (lane 2), 
100 (lane 3) or 20 (lane 4) ng of CL& peptide-coated beads. Extracts of suspended KB cells (b,c) were incubated with 500 ng of a& beads 
(lane 2) or 500 ng of asfi1 beads plus antiserum against the human PI cytoplasmic peptide (b, lane 3). (d) Incubation of suspended KB cell ex- 
tracts with uncoated (lane 2), CX~ peptide-coated (lane 3), or PI peptide-coated (lane 4) beads. The data shown are from duplicate filters or, in 
some cases, from stripping and reprobing of the same filter with a different monoclonal antibody. 
mediated by sequences comprising the C-terminal focal adhe- 
sion targeting (FAT) domain of FAK. Co-immunoprecipita- 
tion experiments using a purified C-terminal fragment of FAK 
confirmed that KB cellular paxillin is indeed competent to 
bind FAK in vitro (Fig. 5). Incubation of KB cell lysates 
with a FLAG epitope-tagged portion of FAK containing 
the paxillin-binding and FAT region [22-241 resulted in effi- 
cient immunoprecipitation of endogenous paxillin by FLAG 
M2 antibody (Fig. 5, lane 1). Thus, paxillin association with 
the p1 cytoplasmic tail could conceivably promote cellular 
targeting of both paxillin and FAK to focal adhesions in 
KB cells. 
4. Discussion 
Our results suggest that paxillin may bind directly to the 
intracellular region of integrin a&. Like two focal adhesion 
proteins known from in vitro studies to associate directly with 
the integrin PI cytoplasmic subunit, talin and a-actinin [34- 
371, paxillin from adherent KB cell extracts associated readily 
with asP1 or p1 peptide-coated beads. Although we cannot 
entirely rule out the possibility that binding of paxillin to p1 
beads might be mediated by another protein that could be 
associated with paxillin, two lines of evidence suggest that 
paxillin may interact directly with the PI cytoplasmic domain. 
First, binding of paxillin to o/& or PI beads was still detected 
in extracts of KB cells kept in suspension to disrupt pre- 
formed focal adhesion complexes. In contrast, vinculin, which 
is known to form complexes with both talin and paxillin 
[24,38], was found in association with a& beads only from 
extracts of KB cells spread on fibronectin. Second, we ob- 
tained in vitro evidence consistent with a direct physical inter- 
action between purified recombinant GST-paxillin and the p1 
cytoplasmic domain. 
In addition to its integrin-binding activity, co-immunopre- 
cipitation experiments using an epitope-tagged C-terminal 
FAT domain of FAK indicated that KB cellular paxillin is 
competent to bind FAK. This finding is in good agreement 
with earlier studies showing that paxillin forms a stable com- 
plex with FAK [22] in adherent or suspended CE fibroblasts 
[23], as well as in a T cell line [24] utilizing sequences compris- 
ing the FAK C-terminal FAT domain. Thus, direct physical 
association of paxillin with the integrin p1 intracellular sub- 
unit may be an important factor in localization of FAK, as 
well as paxillin itself, to focal adhesion sites. Recently, Schal- 
ler et al. [42] reported direct binding of FAK to peptides 
based on the integrin PI cytoplasmic subunit in lysates of 
CE cells engineered to over-express FAK. This interaction is 
likely to have important implications in FAK activation, but 
is unlikely to be responsible for targeting of FAK to focal 
adhesions as integrin binding is apparently mediated by se- 
quences at the FAK N-terminus [42]. In the present work, we 
were not able to detect significant levels of association of 
endogenous KB cellular FAK with a& beads or p1 beads 
(data not shown) under conditions where binding of cellular 
paxillin was easily detected, supporting the view that paxillin 
binding to p1 occurs independently of FAK. Recent availabil- 
ity of a FAK-deficient mouse [45] will make it possible to 
ascertain whether paxillin localizes appropriately in vivo to 
focal contacts in the absence of FAK. Inability to detect 
FAK association with a& beads in our experiments could 
reflect prohibitively low protein levels of endogenous FAK in 












Fig. 4. Interaction of purified GST-paxillin with the pi cytoplasmic domain peptide. GST-paxillin or GST were expressed in E. coli and purified 
using glutathione-Sepharose. Binding to pi beads was assayed as described in Section 2. Bead complexes were resolved by SDS-PAGE and ana- 
lyzed by immunoblotting with anti-paxillin antibody (a) or silver staining (b). PI peptide-coated beads were incubated with 5 ng of either GST 
(lane 1) or GST-paxillin (lane 3), while in lane 2, control uncoated beads were incubated with GST-paxillin. Purified preparations of GST and 
GST-paxillin (10 ng each) are shown in lanes 4 and 5, respectively. Molecular masses of marker proteins are indicated in kDa. The 60 kDa 
protein visible in lanes l-3 of (b) is streptavidin (SA) originating from Dynabeads M-280. 
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KB cells compared to the system utilized by Schaller et al. [42] 
or low affinity of the FAK-integrin interaction. 
Emerging evidence supports the view that integrin cytoplas- 
mic regions act not only as templates for the formation of 
focal adhesion structures, but also in the recruitment of 
PTKs and other proteins with signaling function, including 
paxillin. It is attractive to speculate that one role of paxillin 
and, possibly, of talin which like paxillin forms complexes 
with both the integrin l31 intracellular domain [36,37] and 
Fig. 5. KB cellular paxillin associates with FAK. A C-terminal frag- 
ment of FAK including the FAT domain was expressed in E. coli 
as a FLAG epitope-tagged fusion and immunoatfinity purified as 
described in Section 2. Total cell lvsates (200 I.& from adherent KB 
cells were incubated with 2 pg (lane 1) or 0 Gz(lane 2) of purified 
FAT protein followed by immunoprecipitation with anti-FLAG M2 
antibody. Lane 3 shows a control immunoprecipitation from 200 ug 
of KB total cell lysate using anti-paxillin antibody. Immunoprecipi- 
tates were resolved by immunoblotting with anti-paxillin. 
FAK [46], might be to help position cellular PTKs in proxim- 
ity to integrin cytoplasmic domains, thereby facilitating their 
activation in response to integrin receptor occupancy. Thus, 
despite their small size and limited amino acid sequence in- 
formation, integrin intracellular domains appear to function 
as versatile signal transducers through multiple associations 
with regulatory components of focal adhesion networks. 
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